BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37061330)

  • 1. CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells.
    Nilmani ; D'costa M; Bothe A; Das S; Udhaya Kumar S; Gnanasambandan R; George Priya Doss C
    Adv Protein Chem Struct Biol; 2023; 135():125-177. PubMed ID: 37061330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip).
    Chen WJ; Chang CY; Lin JK
    Biochem Pharmacol; 2003 Jun; 65(11):1777-85. PubMed ID: 12781329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
    Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
    Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
    Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
    Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
    Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
    Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p27 and leukemia: cell cycle and beyond.
    Roy A; Banerjee S
    J Cell Physiol; 2015 Mar; 230(3):504-9. PubMed ID: 25205053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent and heterogenous expression of the cyclin-dependent kinase inhibitor, p27KIP1, in rat hearts during development.
    Koh KN; Kang MJ; Frith-Terhune A; Park SK; Kim I; Lee CO; Koh GY
    J Mol Cell Cardiol; 1998 Mar; 30(3):463-74. PubMed ID: 9515024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
    McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
    Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.
    Hirai H; Roussel MF; Kato JY; Ashmun RA; Sherr CJ
    Mol Cell Biol; 1995 May; 15(5):2672-81. PubMed ID: 7739547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative regulators of cyclin-dependent kinases and their roles in cancers.
    Lee MH; Yang HY
    Cell Mol Life Sci; 2001 Nov; 58(12-13):1907-22. PubMed ID: 11766887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase pathways as targets for cancer treatment.
    Shapiro GI
    J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
    Santamaria D; Ortega S
    Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta.
    Ravitz MJ; Wenner CE
    Adv Cancer Res; 1997; 71():165-207. PubMed ID: 9111866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development.
    Watanabe G; Pena P; Shambaugh GE; Haines GK; Pestell RG
    Brain Res Dev Brain Res; 1998 Jun; 108(1-2):77-87. PubMed ID: 9693786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
    Calbó J; Serna C; Garriga J; Graña X; Mazo A
    Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.